logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ASCO 2019 — Combination checkpoint blockade effective for neoadjuvant NSCLC therapy

Adding ipilimumab to nivolumab boosts major pathologic response rate.